Loading...
Market
What percentage of eligible individuals will receive the at-home FluMist nasal spray in the first flu season of availability?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
CDC vaccination data and reports.
Story
FDA Approves First At-Home FluMist Nasal Spray for Self-Administration
Sep 20, 2024, 08:36 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. The vaccine, which is licensed for individuals aged 2 to 49, will be available for order online through a third-party pharmacy platform starting next flu season. The approval is part of the FDA's broader effort to expand consumer access to medicines, reduce healthcare costs, and barriers to care. FluMist contains a weakened live virus and aims to prevent influenza caused by virus subtypes A and B. This self-administered alternative to flu shots is expected to increase accessibility and uptake of influenza immunization.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
0-10 • 25%
11-25 • 25%
26-40 • 25%
41-50 • 25%
Yes • 50%
No • 50%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
Less than 1,000 • 25%
1,000-2,000 • 25%
2,000-3,000 • 25%
More than 3,000 • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%